Choi Kyung Seek, Chung J K, Lim Sang Hyun
Department of Ophthalmology, Soonchunhyang University, College of Medicine, Yongsan-gu, Seoul, Korea.
Korean J Ophthalmol. 2007 Mar;21(1):11-7. doi: 10.3341/kjo.2007.21.1.11.
To evaluate therapeutic effects and usefulness of a combination treatment of intravitreal injection of triamcinolone acetonide (IVTA) and panretinal photocoagulation (PRP) in patients with clinically significant macular edema secondary to proliferative diabetic retinopathy (PDR).
Visual acuity test, fundoscopy, fluorescein angiography, and optical coherence tomography (OCT) were taken in 20 patients (20 eyes) of macular edema and PDR. A combination of intravitreal injection of triamcinolone acetonide and PRP was performed in 10 patients (10 eyes) and a combination of focal or grid laser photocoaqulation and PRP in the remaining 10 eyes. The postoperative outcomes were compared between the two combination treatments by best corrected visual acuity (BCVA), tonometry, fluorescein angiography, and OCT at 2 weeks, 1, 2, and 3 months.
Average BCVA (log MAR) significantly improved from preoperative 0.56-/+0.20 to 0.43-/+0.08 at 1 month (P=0.042) and it was maintained until 3 months after a combination of IVTA and PRP in 10 eyes (P=0.007). The thickness of fovea decreased from average 433.3-/+114.9 micrometer to average 279.5-/+34.1 micrometer at 2 weeks after combined treatment of IVTA and PRP (P=0.005), which was significantly maintained until 3 months, but there was a transient visual disturbance and no significant difference in thickness of the fovea before and after treatment in the groups with PRP and focal or grid laser photocoagulation.
A combination of IVTA and PRP might be an effective treatment modality in the treatment of macular edema and PDR and prevent the subsequent PRP-induced macular edema result in visual dysfunction. In combination with PRP, IVTA might be more effective than focal or grid laser photocoagulation and PRP for reducing diabetic macular edema and preventing aggravation of macular edema without transient visual disturbance in patients requiring immediate PRP.
评估玻璃体内注射曲安奈德(IVTA)联合全视网膜光凝(PRP)治疗增生性糖尿病视网膜病变(PDR)继发的临床显著性黄斑水肿患者的治疗效果及实用性。
对20例(20只眼)黄斑水肿合并PDR患者进行视力检查、眼底镜检查、荧光素血管造影及光学相干断层扫描(OCT)。10例(10只眼)患者接受玻璃体内注射曲安奈德联合PRP治疗,其余10只眼接受局部或格栅激光光凝联合PRP治疗。在术后2周、1个月、2个月和3个月时,通过最佳矫正视力(BCVA)、眼压测量、荧光素血管造影及OCT对两种联合治疗的术后结果进行比较。
10只接受IVTA联合PRP治疗的眼睛,平均BCVA(对数最小分辨角)从术前的0.56±0.20显著改善至1个月时的0.43±0.08(P = 0.042),并维持至3个月(P = 0.007)。IVTA联合PRP治疗后2周,黄斑中心凹厚度从平均433.3±114.9微米降至平均279.5±34.1微米(P = 0.005),并显著维持至3个月,但在接受PRP及局部或格栅激光光凝治疗的组中,出现短暂视力障碍,且治疗前后黄斑中心凹厚度无显著差异。
IVTA联合PRP可能是治疗黄斑水肿合并PDR的有效治疗方式,可预防后续PRP引起的黄斑水肿导致视力功能障碍。对于需要立即进行PRP的患者,与PRP联合使用时,IVTA在减轻糖尿病性黄斑水肿及预防黄斑水肿加重方面可能比局部或格栅激光光凝联合PRP更有效,且不会引起短暂视力障碍。